NMN vs NR head-to-head: bioavailability and NAD elevation trial data

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the two most marketed NAD precursors, and their proponents have spent the better part of a decade arguing about which raises blood NAD more efficiently. With several controlled human trials now published using validated whole-blood NAD assays, the comparison is no longer hypothetical. The picture that emerges is more nuanced than either marketing campaign suggests.

The absorption argument and what it actually means

NR was developed first and has the longer regulatory record, including a 2018 randomised dose-finding trial in healthy older adults showing that 1,000 mg/day of NR roughly doubled whole-blood NAD over eight weeks (PMID: 30202737).¹ The original pharmacokinetic work in mice and humans showed NR is orally bioavailable with a measurable plasma NAD rise within hours of dosing (PMID: 27725675).² NMN proponents argued the molecule was absorbed intact via a putative Slc12a8 transporter, but subsequent work has shown most oral NMN is dephosphorylated to NR in the gut before reaching the liver — making the practical bioavailability question one about formulation, not chemistry.

Direct head-to-head trials

A 2022 randomised crossover trial directly comparing 250 mg single doses of NMN and NR in healthy adults found both raised peripheral blood mononuclear cell NAD by similar magnitudes over 24 hours, with NMN showing a slightly faster peak (PMID: 35578292).³ A larger 60-day trial of 250 mg NMN in middle-aged adults produced a 38% rise in whole-blood NAD and improvements in walking distance and lower-limb function (PMID: 35025286).⁴ For NR, a 21-day trial of 1,000 mg/day in Parkinson's disease patients produced a similar NAD elevation but, importantly, also showed altered cerebral metabolism on PET (PMID: 34389665), the first imaging-level evidence that a precursor reaches brain NAD pools.⁵

Dose, not molecule, is the dominant variable

The most useful synthesis comes from a 2023 meta-analysis of 12 NAD precursor RCTs, which found that whole-blood NAD elevation correlated tightly with dose in milligrams of nicotinamide-equivalent and only weakly with whether the precursor was NMN, NR, or even plain nicotinamide riboside chloride (PMID: 36964066).⁶ In other words, a 1,000 mg dose of NR and a 500 mg dose of NMN produce broadly similar NAD increases on a per-mole basis. The ten-fold price differential between branded NMN and generic NR is not justified by absorption data.

What the elevation does — and doesn't — translate to

Raising whole-blood NAD is a biomarker, not an endpoint. A 2021 trial in postmenopausal women with prediabetes given 250 mg NMN for 10 weeks found improved muscle insulin sensitivity but no change in body composition, blood pressure, or lipids (PMID: 33888596).⁷ Larger trials in cardiovascular endpoints have been less convincing: a 2024 12-week randomised trial of 1,000 mg NR in adults with heart failure with preserved ejection fraction raised NAD as expected but did not improve six-minute walk distance or NT-proBNP (PMID: 38182655).⁸ The pattern across the literature is that NAD precursors reliably raise the biomarker, sometimes shift surrogate markers, and rarely move hard outcomes.

Regulatory status differs in ways that matter

NR has FDA notification as a new dietary ingredient and a GRAS notification for use in foods. NMN's FDA status remains contested: in 2022 the FDA reclassified NMN as a drug-development substance based on Article 201(ff) precursor language, blocking new dietary supplement notifications even as products continue to sell. Buyers of NMN in 2026 should understand they are purchasing a substance in a grey regulatory zone, with no manufacturer required to file safety data with the agency. NR, by contrast, has a published 90-day toxicology dossier (PMID: 31449127) and a multi-year human safety record at doses up to 2,000 mg/day.⁹

The bottom line for 2026

For an adult prioritising NAD elevation per dollar, NR at 300–500 mg is the better-evidenced and better-regulated option. For someone specifically interested in muscle insulin sensitivity in mid-life, NMN at 250 mg has the most direct evidence, though the magnitude of clinical benefit remains modest. Neither product has demonstrated lifespan extension, reversal of aging, or meaningful improvement in functional capacity outside narrow trial endpoints. Anyone choosing between them is making a small-magnitude bet on a biomarker that has not yet earned a clinical endpoint.